Triple oral lipid lowering treatment
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndromes
Conditions
Acute Coronary Syndromes, Secondary Prevention, Lipids
Trial Timeline
Sep 1, 2026 → Aug 1, 2027
NCT ID
NCT07440381About Triple oral lipid lowering treatment
Triple oral lipid lowering treatment is a phase 3 stage product being developed by Daiichi Sankyo for Acute Coronary Syndromes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07440381. Target conditions include Acute Coronary Syndromes, Secondary Prevention, Lipids.
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndromes were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07440381 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acute Coronary Syndromes